Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

1. (Currently Amended) A compound of the formula:



or a pharmaceutically acceptable ~~form~~ salt thereof, wherein:

A and B are independently CR_{2a} or N;

D, E and F are independently CH or N;

X and Y are independently CR_x or N;

R_x is independently chosen at each occurrence from hydrogen, C_1-C_6alkyl, amino, and mono- and di-(C_1-C_6alkyl)amino;

Z is O or NR_z; wherein R_z is hydrogen, C_1-C_6alkyl or taken together with R_{1a} to form a fused heterocyclic ring having from 5 to 7 ring members, wherein the fused heterocyclic ring is substituted with from 0 to 2 substituents independently chosen from halogen, cyano, C_1-C_6alkyl, C_1-C_6alkoxy and C_1-C_6haloalkyl;

R_{1a} is:

(i) chosen from halogen, cyano, -COOH, C_1-C_6alkyl, C_1-C_6alkoxy, C_1-C_6haloalkyl, C_1-C_6haloalkoxy, mono- and di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, mono- and di-(C_1-C_6alkyl)sulfonamido, and mono- and di-(C_1-C_6alkyl)aminocarbonyl;

(ii) taken together with R_z to form a fused heterocyclic ring; or

(iii) taken together with R_4 to form a fused carbocyclic ring;

R_1 represents from 0 to 2 substituents independently chosen from halogen, hydroxy, amino, cyano, -COOH, C_1-C_6alkyl, C_1-C_6alkoxy, C_2-C_6alkyl ether, C_2-C_6alkanoyl, C_3-C_6alkanone, C_1-C_6haloalkyl, C_1-C_6haloalkoxy, mono- and di-(C_1-C_6alkyl)amino,

C_1-C_6alkylsulfonyl, mono- and di-(C_1-C_6alkyl)sulfonamido, and mono- and di-(C_1-C_6alkyl)aminocarbonyl;

R_2 and each R_{2a} are independently chosen from hydrogen, hydroxy, amino, halogen, C_1-C_6alkyl, C_1-C_6haloalkyl, C_2-C_6alkyl ether, C_2-C_6alkanoyl, C_3-C_6alkanone, mono- and di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, mono- and di-(C_1-C_6alkyl)sulfonamido, and mono- and di-(C_1-C_6alkyl)aminocarbonyl;

R_3 is selected from:

(i) halogen, hydroxy and haloC_1-C_6alkyl;

(ii) phenylC_0-C_4alkyl and pyridylC_0-C_4alkyl; and

(iii) groups of the formula:



wherein

L is a single covalent bond or C_1-C_6alkylene;

R_5 and R_6 are:

(a) independently chosen from hydrogen, C_1-C_8alkyl, C_1-C_8alkenyl, C_2-C_8alkanoyl, (C_3-C_8cycloalkyl)C_0-C_4alkyl, (3- to 7-membered heterocycloalkyl)C_0-C_4alkyl, phenylC_0-C_6alkyl, pyridylC_0-C_6alkyl and groups that are joined to L to form a 4- to 7-membered heterocycloalkyl, such that if L is a single bond, then R_5 and R_6 are not phenyl or pyridyl; or

(b) taken together, with the N to which they are bound, to form a 4- to 7-membered heterocycloalkyl; and

R_7 is C_1-C_8alkyl, (C_3-C_8cycloalkyl)C_0-C_4alkyl, C_1-C_8alkenyl, C_2-C_8alkanoyl, phenylC_0-C_6alkyl, pyridylC_0-C_6alkyl or a group that is joined to L to form a 4- to 7-membered heterocycloalkyl;

wherein each of (ii) and (iii) is substituted with from 0 to 4 substituents independently chosen from halogen, cyano, amino, hydroxy, oxo, C_1-C_6alkyl, C_3-C_8cycloalkyl, C_2-C_6alkyl ether, C_1-C_6alkoxy, C_2-C_6alkanoyl, C_1-C_6haloalkyl, mono- and di-(C_1-C_6alkyl)amino, phenyl, 5- to 6-membered heteroaryl and 4- to 8-membered heterocycloalkyl, wherein each phenyl, heteroaryl and heterocycloalkyl is substituted with from 0 to 2 secondary substituents independently chosen from halogen, hydroxy, amino, cyano, C_1-C_4alkyl, C_1-C_4alkoxy and C_1-C_4haloalkyl; and

R_4 is hydrogen, C_1-C_6alkyl or taken together with R_{1a} to form a fused carbocyclic ring.

2-5. (Cancelled)..

6. (Currently Amended) A compound or pharmaceutically acceptable ~~form~~ salt thereof according to claim 5, wherein R_3 is a group of the formula $-N(R_5)(R_6)$, wherein R_5 and R_6 are:

(a) independently chosen from hydrogen, C_1-C_6alkyl, C_3-C_8cycloalkyl, C_1-C_6alkenyl, benzyl and $-CH_2$-pyridyl; or

(b) taken together, with the N to which they are bound, to form a 4- to 7-membered heterocycloalkyl; and

wherein each of which alkyl, cycloalkyl, alkenyl, benzyl, pyridyl and heterocycloalkyl is substituted with from 0 to 3 substituents independently chosen from halogen, amino, cyano, hydroxy, C_1-C_4alkyl, C_2-C_4alkyl ether, C_1-C_4alkoxy, C_1-C_4haloalkyl and mono- and di-(C_1-C_4alkyl)amino.

7. (Currently Amended) A compound or pharmaceutically acceptable salt ~~form~~ thereof according to claim 6, wherein R_3 is mono- or di-(C_1-C_6alkyl)amino.

8. (Currently Amended) A compound or pharmaceutically acceptable salt ~~form~~ thereof according to claim 6, wherein R_3 is benzylamino or $-NH-CH_2$-pyridyl, each of which is substituted with from 0 to 2 substituents independently chosen from halogen, amino, hydroxy, cyano, C_1-C_4alkyl, C_1-C_4alkoxy, and C_1-C_4haloalkyl.

9. (Currently Amended) A compound or pharmaceutically acceptable salt ~~form~~ thereof according to claim 6, wherein R_3 is pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl or azepanyl, each of which is substituted with from 0 to 3 substituents independently chosen from halogen, amino, hydroxy, cyano, C_1-C_4alkyl, C_1-C_4alkoxy, and C_1-C_4haloalkyl.

10. (Currently Amended) A compound or pharmaceutically acceptable ~~form~~salt thereof according to claim 1, wherein R_3 is a group of the formula -O-R_7 wherein R_7 is hydrogen, C_1-C_6alkyl, phenylC_0-C_6alkyl or pyridylC_0-C_6alkyl, wherein each alkyl, phenyl and pyridyl is substituted with from 0 to 3 substituents independently chosen from halogen, hydroxy, cyano, amino, C_1-C_4alkyl, C_1-C_4haloalkyl and C_1-C_4alkoxy.

11-12. (Cancelled).

13. (Currently Amended) A compound or pharmaceutically acceptable salt ~~form~~ thereof according to claim 1, wherein R_2 and each R_{2a} are independently chosen from hydrogen, amino, halogen, C_1-C_4alkyl, C_1-C_4haloalkyl, C_1-C_4alkylsulfonyl and mono- and di-(C_1-C_4alkyl)sulfonamido, and wherein at least one of R_2 or R_{2a} is not hydrogen.

14-18. (Cancelled).

19. (Currently Amended) A compound or pharmaceutically acceptable ~~form~~salt thereof according to claim 1, wherein the compound has the formula:



20. (Cancelled).

21. (Currently Amended) A compound or pharmaceutically acceptable ~~form~~salt thereof according to claim 1, wherein the compound has the formula:



22-23. (Cancelled).

24. (Currently Amended) A compound or pharmaceutically acceptable ~~form~~salt thereof according to claim 1, wherein the compound has the formula:



25-27. (Cancelled).

28. (Currently Amended) A compound of the formula:



or a pharmaceutically acceptable ~~form~~salt thereof, wherein:

A is CR_{2a} or N;

D, E, F and U are independently CH or N;

X and Y are independently CR_x or N;

R_x is independently chosen at each occurrence from hydrogen, C_1-C_6alkyl, amino, cyano, and mono- and di-(C_1-C_6alkyl)amino;

Z is O or NR_z; wherein R_z is hydrogen, C_1-C_6alkyl or taken together with R_{1a} to form a fused heterocyclic ring having from 5 to 7 ring members, wherein the fused heterocyclic ring is substituted with from 0 to 2 substituents independently chosen from halogen, cyano, C_1-C_6alkyl, C_1-C_6alkoxy and C_1-C_6haloalkyl;

V is O or NR_v; wherein R_v is hydrogen, C_1-C_6alkyl or taken together with an R_8 to form a fused heterocyclic ring having from 5 to 7 ring members, wherein the fused heterocyclic ring is substituted with from 0 to 2 substituents independently chosen from halogen, cyano, C_1-C_6alkyl, C_1-C_6alkoxy and C_1-C_6haloalkyl;

R_{1a} is:

(i) chosen from halogen, cyano, -COOH, C_1-C_6alkyl, C_1-C_6alkoxy, C_1-C_6haloalkyl, C_1-C_6haloalkoxy, mono- and di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, mono- and di-(C_1-C_6alkyl)sulfonamido, and mono- and di-(C_1-C_6alkyl)aminocarbonyl; or

(ii) taken together with R_z to form a fused heterocyclic ring; or

(iii) taken together with R_4 to form a fused carbocyclic ring;

R_1 represents from 0 to 2 substituents independently chosen from halogen, hydroxy, amino, cyano, -COOH, C_1-C_6alkyl, C_1-C_6alkoxy, C_2-C_6alkyl ether, C_2-C_6alkanoyl, C_3-C_6alkanone, C_1-C_6haloalkyl, C_1-C_6haloalkoxy, mono- and di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, mono- and di-(C_1-C_6alkyl)sulfonamido, and mono- and di-(C_1-C_6alkyl)aminocarbonyl;

R_8 represents from 0 to 3 substituents independently chosen from halogen, hydroxy, amino, cyano, C_1-C_6alkyl, C_1-C_6alkoxy, C_2-C_6alkyl ether, C_2-C_6alkanoyl, C_3-C_6alkanone, C_1-C_6haloalkyl, C_1-C_6haloalkoxy, mono- and di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, mono- and di-(C_1-C_6alkyl)sulfonamido, and mono- and di-(C_1-C_6alkyl)aminocarbonyl; or R_8 is taken together with R_v to form a fused heterocyclic ring;

R_2 and each R_{2a} are independently chosen from hydrogen, hydroxy, amino, cyano, halogen, C_1-C_6alkyl, C_1-C_6haloalkyl, C_2-C_6alkyl ether, C_2-C_6alkanoyl, C_3-C_6alkanone, mono- and di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, mono- and di-(C_1-C_6alkyl)sulfonamido, and mono- and di-(C_1-C_6alkyl)aminocarbonyl; and

R_4 is hydrogen, C_1-C_6alkyl or taken together with R_{1a} to form a fused carbocyclic ring.

29-42. (Cancelled).

43. (Currently Amended) A compound of the formula:



or a pharmaceutically acceptable ~~form~~salt thereof, wherein:

A, D, E and F are independently CH or N;

X and Y are independently CR_x or N;

R_x is independently chosen at each occurrence from hydrogen, C_1-C_6alkyl, amino, and mono- and di-(C_1-C_6alkyl)amino;

R_{1a} is:

(i) chosen from halogen, cyano, amino, -COOH, C_1-C_6alkyl, C_1-C_6alkoxy, C_1-C_6haloalkyl, C_1-C_6haloalkoxy, mono- and di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, mono- and di-(C_1-C_6alkyl)sulfonamido, and mono- and di-(C_1-C_6alkyl)aminocarbonyl; or

(ii) taken together with R_4 to form a fused carbocyclic ring;

R_1 represents from 0 to 2 substituents independently chosen from halogen, hydroxy, amino, cyano, -COOH, C_1-C_6alkyl, C_1-C_6alkoxy, C_2-C_6alkyl ether, C_2-C_6alkanoyl, C_3-C_6alkanone, C_1-C_6haloalkyl, C_1-C_6haloalkoxy, mono- and di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, mono- and di-(C_1-C_6alkyl)sulfonamido, and mono- and di-(C_1-C_6alkyl)aminocarbonyl;

R_2 is chosen from hydroxy, amino, cyano, halogen, hydroxy, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_2-C_6alkyl ether, C_2-C_6alkanoyl, C_3-C_6alkanone, mono- and di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, mono- and di-(C_1-C_6alkyl)sulfonamido, and mono- and di-(C_1-C_6alkyl)aminocarbonyl;

R_{2a} represents from 0 to 2 substituents independently chosen from hydroxy, amino, cyano, halogen, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_2-C_6alkyl ether, C_2-C_6alkanoyl, C_3-C_6alkanone, mono- and di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, mono- and di-(C_1-C_6alkyl)sulfonamido, and mono- and di-(C_1-C_6alkyl)aminocarbonyl;

R_3 is selected from:

(i) halogen, hydroxy and haloC_1-C_6alkyl;

(ii) phenylC_0-C_4alkyl and pyridylC_0-C_4alkyl; and

(iii) groups of the formula:

 or

wherein

L is a single covalent bond or C_1-C_6alkylene;

R_5 and R_6 are:

(a) independently chosen from hydrogen, C_1-C_8alkyl, C_1-C_8alkenyl, C_2-C_8alkanoyl, (C_3-C_8cycloalkyl)C_0-C_4alkyl, (3- to 7-membered heterocycloalkyl)C_0-C_4alkyl, phenylC_0-C_6alkyl, pyridylC_0-C_6alkyl and groups that are joined to L to form a 4- to 7-membered heterocycloalkyl, such that if L is a single bond, then R_5 and R_6 are not phenyl or pyridyl; or

(b) taken together, with the N to which they are bound, to form a 4- to 7-membered heterocycloalkyl; and

R_7 is C_1-C_8alkyl, C_3-C_8cycloalkyl(C_0-C_4alkyl), C_1-C_8alkenyl, C_2-C_8alkanoyl, phenylC_0-C_6alkyl, pyridylC_0-C_6alkyl or a group that is joined to L to form a 4- to 7-membered heterocycloalkyl;

wherein each of (ii) and (iii) is substituted with from 0 to 4 substituents independently chosen from halogen, cyano, amino, hydroxy, oxo, C_1-C_6alkyl, C_3-C_8cycloalkyl, C_2-C_6alkyl ether, C_1-C_6alkoxy, C_2-C_6alkanoyl, C_1-C_6haloalkyl, mono- and di-(C_1-C_6alkyl)amino, phenyl, 5- to 6-membered heteroaryl and 4- to 8-membered heterocycloalkyl, wherein each phenyl, heteroaryl and heterocycloalkyl is substituted with from 0 to 2 secondary substituents independently chosen from halogen, hydroxy, amino, cyano, C_1-C_4alkyl, C_1-C_4alkoxy and C_1-C_4haloalkyl; and

R_4 is hydrogen, C_1-C_6alkyl or taken together with R_{1a} to form a fused carbocyclic ring.

44-57. (Cancelled).

58. (Currently Amended) A pharmaceutical composition, comprising at least one compound or pharmaceutically acceptable ~~form~~salt thereof according to ~~any one of~~

~~claims 1, 28 or 43~~claim 1 in combination with a physiologically acceptable carrier or excipient.

59. (Original) A pharmaceutical composition according to claim 58 wherein the composition is formulated as an injectible fluid, an aerosol, a cream, a gel, a pill, a capsule, a syrup or a transdermal patch.

60. (Currently Amended) A method for reducing calcium conductance of a cellular capsaicin receptor, comprising contacting a cell expressing a capsaicin receptor with at least one compound having the formula:



or a pharmaceutically acceptable ~~form~~salt thereof, wherein:

Ar_1 is phenyl or a 6-membered aromatic heterocycle, each of which is substituted with from 0 to 4 substituents independently chosen from R_1;

Ar_2 is phenyl, pyridyl or pyrimidyl, each of which is substituted with from 0 to 4 substituents independently chosen from R_2;

X and Y are independently CR_x or N; wherein R_x is independently chosen at each occurrence from hydrogen, C_1-C_6alkyl, amino, mono- and di-(C_1-C_6alkyl)amino, and cyano;

Z is O or NR_z; wherein R_z is hydrogen, C_1-C_6alkyl or taken together with a R_1 moiety to form a fused, partially saturated heterocyclic ring having from 5 to 7 ring members, wherein the fused heterocyclic ring is substituted with from 0 to 2 substituents independently chosen from halogen, cyano, C_1-C_6alkyl, C_1-C_6alkoxy and C_1-C_6haloalkyl;

Each R_1 is independently:

(i) chosen from halogen, hydroxy, amino, cyano, -COOH, C_1-C_6alkyl, C_1-C_6alkoxy, C_2-C_6alkyl ether, C_2-C_6alkanoyl, C_3-C_6alkanone, C_1-C_6haloalkyl, C_1-C_6haloalkoxy, mono- and di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, mono- and di-(C_1-C_6alkyl)sulfonamido, and mono- and di-(C_1-C_6alkyl)aminocarbonyl;

(ii) taken together with R_z to form a fused heterocyclic ring; or

(iii) taken together with R_4 to form a fused carbocyclic ring;

Each R_2 is independently:

(i) chosen from hydrogen, hydroxy, amino, cyano, halogen, -COOH, aminocarbonyl, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_2-C_6alkyl ether, C_2-C_6alkanoyl, C_3-C_6alkanone, mono- and di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, mono- and di-(C_1-C_6alkyl)sulfonamido, and mono- and di-(C_1-C_6alkyl)aminocarbonyl; or

(ii) taken together with an adjacent R_2 to form a fused 5- to 10-membered carbocyclic or heterocyclic group that is substituted with from 0 to 3 substituents independently chosen from halogen and C_1-C_6alkyl;

R_3 is selected from:

(i) hydrogen, hydroxy and halogen;

(ii) C_1-C_6alkyl, C_3-C_8cycloalkyl, phenylC_0-C_4alkyl and pyridylC_0-C_4alkyl; and

(iii) groups of the formula



wherein

L is a single covalent bond or C_1-C_6alkylene;

R_5 and R_6 are:

(a) independently chosen from hydrogen, C_1-C_8alkyl, C_1-C_8alkenyl, C_2-C_8alkanoyl, (C_3-C_8cycloalkyl)C_0-C_4alkyl, (3- to 7-membered heterocycloalkyl)C_0-C_4alkyl, phenylC_0-C_6alkyl, pyridylC_0-C_6alkyl and groups that are joined to L to form a 4- to 7-membered heterocycloalkyl; or

(b) taken together, with the N to which they are bound, to form a 4- to 7-membered heterocycloalkyl; and

R_7 is C_1-C_8alkyl, C_3-C_8cycloalkyl(C_0-C_4alkyl), C_1-C_8alkenyl, C_2-C_8alkanoyl, phenylC_0-C_6alkyl, pyridylC_0-C_6alkyl or a group that is joined to L to form a 4- to 7-membered heterocycloalkyl;

wherein each of (ii) and (iii) is optionally substituted, preferably with from 0 to 4 substituents independently chosen from halogen, cyano, amino, hydroxy, oxo, C_1-C_6alkyl, C_3-C_8cycloalkyl, C_2-C_6alkyl ether, C_1-C_6alkoxy, C_2-C_6alkanoyl, C_1-C_6haloalkyl, mono- and di-(C_1-C_6alkyl)amino, phenyl, 5- to 6-membered heteroaryl and 4- to 8-membered heterocycloalkyl, wherein each phenyl, heteroaryl and heterocycloalkyl is substituted with from 0 to 2 secondary substituents independently

chosen from halogen, hydroxy, amino, cyano, C_1-C_4alkyl, C_1-C_4alkoxy and C_1-C_4haloalkyl; and

each R_4 is hydrogen, C_1-C_6alkyl or taken together with a R_1 to form a fused carbocyclic ring;

and thereby reducing calcium conductance of the capsaicin receptor.

61-81. (Cancelled).

82. (Currently Amended) A method for treating a condition responsive to capsaicin receptor modulation in a patient, comprising administering to the patient a capsaicin receptor modulatory amount of a compound having the formula:



or a pharmaceutically acceptable ~~form~~salt thereof, wherein:

Ar_1 is phenyl or a 6-membered aromatic heterocycle, each of which is substituted with from 0 to 4 substituents independently chosen from R_1;

Ar_2 is phenyl, pyridyl or pyrimidyl, each of which is substituted with from 0 to 4 substituents independently chosen from R_2;

X and Y are independently CR_x or N; wherein R_x is independently chosen at each occurrence from hydrogen, C_1-C_6alkyl, amino, mono- and di-(C_1-C_6alkyl)amino, and cyano;

Z is O or NR_z; wherein R_z is hydrogen, C_1-C_6alkyl or taken together with a R_1 moiety to form a fused, partially saturated heterocyclic ring having from 5 to 7 ring members, wherein the fused heterocyclic ring is substituted with from 0 to 2 substituents independently chosen from halogen, cyano, C_1-C_6alkyl, C_1-C_6alkoxy and C_1-C_6haloalkyl;

Each R_1 is independently:

(i) chosen from halogen, hydroxy, amino, cyano, -COOH, C_1-C_6alkyl, C_1-C_6alkoxy, C_2-C_6alkyl ether, C_2-C_6alkanoyl, C_3-C_6alkanone, C_1-C_6haloalkyl, C_1-C_6haloalkoxy, mono- and di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, mono- and di-(C_1-C_6alkyl)sulfonamido, and mono- and di-(C_1-C_6alkyl)aminocarbonyl;

(ii) taken together with R_z to form a fused heterocyclic ring; or

(iii) taken together with R_4 to form a fused carbocyclic ring;

Each R_2 is independently:

(i) chosen from hydrogen, hydroxy, amino, cyano, halogen, -COOH, aminocarbonyl, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_2-C_6alkyl ether, C_2-C_6alkanoyl, C_3-C_6alkanone, mono- and di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, mono- and di-(C_1-C_6alkyl)sulfonamido, and mono- and di-(C_1-C_6alkyl)aminocarbonyl; or

(ii) taken together with an adjacent R_2 to form a fused 5- to 10-membered carbocyclic or heterocyclic group that is substituted with from 0 to 3 substituents independently chosen from halogen and C_1-C_6alkyl;

R_3 is selected from:

(i) hydrogen, hydroxy and halogen;

(ii) C_1-C_6alkyl, C_3-C_8cycloalkyl, phenylC_0-C_4alkyl and pyridylC_0-C_4alkyl; and

(iii) groups of the formula



wherein

L is a single covalent bond or C_1-C_6alkylene;

R_5 and R_6 are:

(a) independently chosen from hydrogen, C_1-C_8alkyl, C_1-C_8alkenyl, C_2-C_8alkanoyl, (C_3-C_8cycloalkyl)C_0-C_4alkyl, (3- to 7-membered heterocycloalkyl)C_0-C_4alkyl, phenylC_0-C_6alkyl, pyridylC_0-C_6alkyl and groups that are joined to L to form a 4- to 7-membered heterocycloalkyl; or

(b) taken together, with the N to which they are bound, to form a 4- to 7-membered heterocycloalkyl; and

R_7 is C_1-C_8alkyl, C_3-C_8cycloalkyl(C_0-C_4alkyl), C_1-C_8alkenyl, C_2-C_8alkanoyl, phenylC_0-C_6alkyl, pyridylC_0-C_6alkyl or a group that is joined to L to form a 4- to 7-membered heterocycloalkyl;

wherein each of (ii) and (iii) is optionally substituted, preferably with from 0 to 4 substituents independently chosen from halogen, cyano, amino, hydroxy, oxo, C_1-C_6alkyl, C_3-C_8cycloalkyl, C_2-C_6alkyl ether, C_1-C_6alkoxy, C_2-C_6alkanoyl, C_1-C_6haloalkyl, mono- and di-(C_1-C_6alkyl)amino, phenyl, 5- to 6-membered heteroaryl and 4- to 8-membered heterocycloalkyl, wherein each phenyl, heteroaryl and heterocycloalkyl is substituted with from 0 to 2 secondary substituents independently

chosen from halogen, hydroxy, amino, cyano, C_1-C_4alkyl, C_1-C_4alkoxy and C_1-C_4haloalkyl; and

each R_4 is hydrogen, C_1-C_6alkyl or taken together with a R_1 to form a fused carbocyclic ring;

and thereby alleviating the condition in the patient.

83. (Original) A method according to claim 82, wherein the patient is suffering from (i) exposure to capsaicin, (ii) burn or irritation due to exposure to heat, (iii) burns or irritation due to exposure to light, (iv) burn, bronchoconstriction or irritation due to exposure to tear gas, air pollutants or pepper spray, or (v) burn or irritation due to exposure to acid.

84. (Original) A method according to claim 82, wherein the condition is asthma or chronic obstructive pulmonary disease.

85. (Original) A method according to claim 82, wherein the compound is a compound according to claim 1.

86-87. (Cancelled).

88. (Currently Amended) A method for treating pain in a patient, comprising administering to a patient suffering from pain a capsaicin receptor modulatory amount of at least one compound having the formula:



or a pharmaceutically acceptable ~~form~~salt thereof, wherein:

Ar_1 is phenyl or a 6-membered aromatic heterocycle, each of which is substituted with from 0 to 4 substituents independently chosen from R_1;

Ar_2 is phenyl, pyridyl or pyrimidyl, each of which is substituted with from 0 to 4 substituents independently chosen from R_2;

X and Y are independently CR_x or N; wherein R_x is independently chosen at each occurrence from hydrogen, C_1-C_6alkyl, amino, mono- and di-(C_1-C_6alkyl)amino, and cyano;

Z is O or NR_z; wherein R_z is hydrogen, C_1-C_6alkyl or taken together with a R_1 moiety to form a fused, partially saturated heterocyclic ring having from 5 to 7 ring members, wherein the fused heterocyclic ring is substituted with from 0 to 2 substituents independently chosen from halogen, cyano, C_1-C_6alkyl, C_1-C_6alkoxy and C_1-C_6haloalkyl;

Each R_1 is independently:

(i) chosen from halogen, hydroxy, amino, cyano, -COOH, C_1-C_6alkyl, C_1-C_6alkoxy, C_2-C_6alkyl ether, C_2-C_6alkanoyl, C_3-C_6alkanone, C_1-C_6haloalkyl, C_1-C_6haloalkoxy, mono- and di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, mono- and di-(C_1-C_6alkyl)sulfonamido, and mono- and di-(C_1-C_6alkyl)aminocarbonyl;

(ii) taken together with R_z to form a fused heterocyclic ring; or

(iii) taken together with R_4 to form a fused carbocyclic ring;

Each R_2 is independently:

(i) chosen from hydrogen, hydroxy, amino, cyano, halogen, -COOH, aminocarbonyl, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_2-C_6alkyl ether, C_2-C_6alkanoyl, C_3-C_6alkanone, mono- and di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, mono- and di-(C_1-C_6alkyl)sulfonamido, and mono- and di-(C_1-C_6alkyl)aminocarbonyl; or

(ii) taken together with an adjacent R_2 to form a fused 5- to 10-membered carbocyclic or heterocyclic group that is substituted with from 0 to 3 substituents independently chosen from halogen and C_1-C_6alkyl;

R_3 is selected from:

(i) hydrogen, hydroxy and halogen;

(ii) C_1-C_6alkyl, C_3-C_8cycloalkyl, phenylC_0-C_4alkyl and pyridylC_0-C_4alkyl; and

(iii) groups of the formula



wherein

L is a single covalent bond or C_1-C_6alkylene;

R_5 and R_6 are:

(a) independently chosen from hydrogen, C_1-C_8alkyl, C_1-C_8alkenyl, C_2-C_8alkanoyl, (C_3-C_8cycloalkyl)C_0-C_4alkyl, (3- to 7-membered

heterocycloalkyl)C_0-C_4alkyl, phenylC_0-C_6alkyl, pyridylC_0-C_6alkyl and groups that are joined to L to form a 4- to 7-membered heterocycloalkyl; or

(b) taken together, with the N to which they are bound, to form a 4- to 7-membered heterocycloalkyl; and

R_7 is C_1-C_8alkyl, C_3-C_8cycloalkyl(C_0-C_4alkyl), C_1-C_8alkenyl, C_2-C_8alkanoyl, phenylC_0-C_6alkyl, pyridylC_0-C_6alkyl or a group that is joined to L to form a 4- to 7-membered heterocycloalkyl;

wherein each of (ii) and (iii) is optionally substituted, preferably with from 0 to 4 substituents independently chosen from halogen, cyano, amino, hydroxy, oxo, C_1-C_6alkyl, C_3-C_8cycloalkyl, C_2-C_6alkyl ether, C_1-C_6alkoxy, C_2-C_6alkanoyl, C_1-C_6haloalkyl, mono- and di-(C_1-C_6alkyl)amino, phenyl, 5- to 6-membered heteroaryl and 4- to 8-membered heterocycloalkyl, wherein each phenyl, heteroaryl and heterocycloalkyl is substituted with from 0 to 2 secondary substituents independently chosen from halogen, hydroxy, amino, cyano, C_1-C_4alkyl, C_1-C_4alkoxy and C_1-C_4haloalkyl; and

each R_4 is hydrogen, C_1-C_6alkyl or taken together with a R_1 to form a fused carbocyclic ring;

and thereby alleviating pain in the patient.

89-91. (Cancelled).

92. (Original) A method according to claim 88, wherein the patient is suffering from neuropathic pain.

93. (Original) A method according to claim 88, wherein the pain is associated with a condition selected from: postmastectomy pain syndrome, stump pain, phantom limb pain, oral neuropathic pain, toothache, postherpetic neuralgia, diabetic neuropathy, reflex sympathetic dystrophy, trigeminal neuralgia, osteoarthritis, rheumatoid arthritis, fibromyalgia, Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome, bilateral peripheral neuropathy, causalgia, neuritis, neuronitis, neuralgia, AIDS-related neuropathy, MS-related neuropathy, spinal cord injury-related pain, surgery-related pain, musculoskeletal pain, back pain, headache, migraine, angina, labor, hemorrhoids, dyspepsia, Charcot's pains, intestinal gas, menstruation, cancer, venom exposure, irritable bowel syndrome, inflammatory bowel disease and trauma.

94-99. (Cancelled).

100. (Currently Amended) A method for treating urinary incontinence or overactive bladder in a patient, comprising administering to a patient a capsaicin receptor modulatory amount of a compound having the formula:



or a pharmaceutically acceptable ~~form~~salt thereof, wherein:

Ar_1 is phenyl or a 6-membered aromatic heterocycle, each of which is substituted with from 0 to 4 substituents independently chosen from R_1;

Ar_2 is phenyl, pyridyl or pyrimidyl, each of which is substituted with from 0 to 4 substituents independently chosen from R_2;

X and Y are independently CR_x or N; wherein R_x is independently chosen at each occurrence from hydrogen, C_1-C_6alkyl, amino, mono- and di-(C_1-C_6alkyl)amino, and cyano;

Z is O or NR_z; wherein R_z is hydrogen, C_1-C_6alkyl or taken together with a R_1 moiety to form a fused, partially saturated heterocyclic ring having from 5 to 7 ring members, wherein the fused heterocyclic ring is substituted with from 0 to 2 substituents independently chosen from halogen, cyano, C_1-C_6alkyl, C_1-C_6alkoxy and C_1-C_6haloalkyl;

Each R_1 is independently:

(i) chosen from halogen, hydroxy, amino, cyano, -COOH, C_1-C_6alkyl, C_1-C_6alkoxy, C_2-C_6alkyl ether, C_2-C_6alkanoyl, C_3-C_6alkanone, C_1-C_6haloalkyl, C_1-C_6haloalkoxy, mono- and di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, mono- and di-(C_1-C_6alkyl)sulfonamido, and mono- and di-(C_1-C_6alkyl)aminocarbonyl;

(ii) taken together with R_z to form a fused heterocyclic ring; or

(iii) taken together with R_4 to form a fused carbocyclic ring;

Each R_2 is independently:

(i) chosen from hydrogen, hydroxy, amino, cyano, halogen, -COOH, aminocarbonyl, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_2-C_6alkyl ether, C_2-C_6alkanoyl, C_3-C_6alkanone, mono- and di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, mono- and di-(C_1-C_6alkyl)sulfonamido, and mono- and di-(C_1-C_6alkyl)aminocarbonyl; or

(ii) taken together with an adjacent R_2 to form a fused 5- to 10-membered carbocyclic or heterocyclic group that is substituted with from 0 to 3 substituents independently chosen from halogen and C_1-C_6alkyl;

R_3 is selected from:

(i) hydrogen, hydroxy and halogen;

(ii) C_1-C_6alkyl, C_3-C_8cycloalkyl, phenylC_0-C_4alkyl and pyridylC_0-C_4alkyl; and

(iii) groups of the formula



or


wherein

L is a single covalent bond or C_1-C_6alkylene;

R_5 and R_6 are:

(a) independently chosen from hydrogen, C_1-C_8alkyl, C_1-C_8alkenyl, C_2-C_8alkanoyl, (C_3-C_8cycloalkyl)C_0-C_4alkyl, (3- to 7-membered heterocycloalkyl)C_0-C_4alkyl, phenylC_0-C_6alkyl, pyridylC_0-C_6alkyl and groups that are joined to L to form a 4- to 7-membered heterocycloalkyl; or

(b) taken together, with the N to which they are bound, to form a 4- to 7-membered heterocycloalkyl; and

R_7 is C_1-C_8alkyl, C_3-C_8cycloalkyl(C_0-C_4alkyl), C_1-C_8alkenyl, C_2-C_8alkanoyl, phenylC_0-C_6alkyl, pyridylC_0-C_6alkyl or a group that is joined to L to form a 4- to 7-membered heterocycloalkyl;

wherein each of (ii) and (iii) is optionally substituted, preferably with from 0 to 4 substituents independently chosen from halogen, cyano, amino, hydroxy, oxo, C_1-C_6alkyl, C_3-C_8cycloalkyl, C_2-C_6alkyl ether, C_1-C_6alkoxy, C_2-C_6alkanoyl, C_1-C_6haloalkyl, mono- and di-(C_1-C_6alkyl)amino, phenyl, 5- to 6-membered heteroaryl and 4- to 8-membered heterocycloalkyl, wherein each phenyl, heteroaryl and heterocycloalkyl is substituted with from 0 to 2 secondary substituents independently

chosen from halogen, hydroxy, amino, cyano, C_1-C_4alkyl, C_1-C_4alkoxy and C_1-C_4haloalkyl; and

each R_4 is hydrogen, C_1-C_6alkyl or taken together with a R_1 to form a fused carbocyclic ring;

and thereby alleviating urinary incontinence or overactive bladder in the patient.

101-106. (Cancelled).

107. (Currently Amended) A packaged pharmaceutical preparation, comprising:

(a) a pharmaceutical composition according to claim 58 in a container; and

(b) instructions for using the composition to treat pain, cough, hiccup, itch, urinary incontinence, overactive bladder, or obesity.

108-112. (Cancelled).

113. (Currently Amended) A compound or pharmaceutically acceptable salt thereof selected from the group consisting of (4-*tert*-Butyl-phenyl)-[4-(4-methyl-piperazin-1-yl)-6-(2-trifluoromethyl-benzyloxy)-[1,3,5]triazin-2-yl]-amine, (4-*tert*-Butyl-phenyl)-[4-chloro-6-(2-chloro-benzyloxy)-[1,3,5]triazin-2-yl]-amine;

(4-*tert*-Butyl-phenyl)-[4-chloro-6-(2-methoxy-benzyloxy)-[1,3,5]triazin-2-yl]-amine,

(4-*tert*-Butyl-phenyl)-[4-chloro-6-(2-trifluoromethyl-benzyloxy)-[1,3,5]triazin-2-yl]-amine,

(4-*tert*-Butyl-phenyl)-[4-chloro-6-(3,4-dihydro-1H-isoquinolin-2-yl)-[1,3,5]triazin-2-yl]-amine,

(4-*tert*-Butyl-phenyl)-[4-chloro-6-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-[1,3,5]triazin-2-yl]-amine,

(4-*tert*-Butyl-phenyl)-[4-chloro-6-(6,7-dimethoxy-3-methyl-3,4-dihydro-1H-isoquinolin-2-yl)-[1,3,5]triazin-2-yl]-amine,

(4-*tert*-Butyl-phenyl)-[6-(2-trifluoromethyl-benzyloxy)-pyrimidin-4-yl]-amine,

[4-(2-Chloro-phenyl)-6-(2-trifluoromethyl-benzyloxy)-[1,3,5]triazin-2-yl]-(4-trifluoromethyl-phenyl)-amine,

[4-(2-Trifluoromethyl-benzyloxy)-6-(2-trifluoromethyl-phenyl)-[1,3,5]triazin-2-yl]-(4-trifluoromethyl-phenyl)-amine,

[4,6-Bis-(2-chloro-benzyloxy)-[1,3,5]triazin-2-yl]-(4-*tert*-butyl-phenyl)-amine,

[4,6-Bis-(2-fluoro-benzyloxy)-[1,3,5]triazin-2-yl]-(4-*tert*-butyl-phenyl)-amine,

[4,6-Bis-(2-methoxy-benzyloxy)-[1,3,5]triazin-2-yl]-(4-*tert*-butyl-phenyl)-amine,

[4,6-Bis-(2-trifluoromethyl-benzyloxy)-[1,3,5]triazin-2-yl]-(4-*tert*-butyl-phenyl)-amine,

[4,6-Bis-(2-trifluoromethyl-benzyloxy)-[1,3,5]triazin-2-yl]-(4-trifluoromethyl-phenyl)-amine,

[4,6-Bis-(3-chloro-pyridin-2-ylmethoxy)-[1,3,5]triazin-2-yl]-(4-*tert*-butyl-phenyl)-amine,

[4,6-Bis-(pyridin-2-ylmethoxy)-[1,3,5]triazin-2-yl]-(4-*tert*-butyl-phenyl)-amine,

[4-Chloro-6-(2-trifluoromethyl-benzyloxy)-[1,3,5]triazin-2-yl]-(4-trifluoromethyl-phenyl)-amine,

[4-Cyclopentyloxy-6-(2-trifluoromethyl-benzyloxy)-[1,3,5]triazin-2-yl]-(4-trifluoromethyl-phenyl)-amine,

[4-Ethoxy-6-(2-trifluoromethyl-benzyloxy)-[1,3,5]triazin-2-yl]-(4-trifluoromethyl-phenyl)-amine,

[4-Morpholin-4-yl-6-(2-trifluoromethyl-benzyloxy)-[1,3,5]triazin-2-yl]-(4-trifluoromethyl-phenyl)-amine,

[4-Phenyl-6-(2-trifluoromethyl-benzyloxy)-[1,3,5]triazin-2-yl]-(4-trifluoromethyl-phenyl)-amine,

[4-Pyridin-3-yl-6-(2-trifluoromethyl-benzyloxy)-[1,3,5]triazin-2-yl]-(4-trifluoromethyl-phenyl)-amine,

2-Methyl-4-[4-(2-trifluoromethyl-benzyloxy)-6-(4-trifluoromethyl-phenylamino)-[1,3,5]triazin-2-ylamino]-butan-2-ol,

4-(2-Trifluoromethyl-benzyloxy)-6-(4-trifluoromethyl-phenylamino)-[1,3,5]triazin-2-ol,

6-Methyl-N-(2-trifluoromethyl-benzyl)-N'-(4-trifluoromethyl-phenyl)-[1,3,5]triazine-2,4-diamine,

N-(2-Methoxy-ethyl)-6-(2-trifluoromethyl-benzyloxy)-N'-(4-trifluoromethyl-phenyl)-[1,3,5]triazine-2,4-diamine,

N-(2-Morpholin-4-yl-ethyl)-6-(2-trifluoromethyl-benzyloxy)-N'-(4-trifluoromethyl-phenyl)-[1,3,5]triazine-2,4-diamine,

N-(3-Methyl-butyl)-6-(2-trifluoromethyl-benzyloxy)-N'-(4-trifluoromethyl-phenyl)-[1,3,5]triazine-2,4-diamine,

N-(4-*tert*-Butyl-phenyl)-6-(2-chloro-benzyloxy)-[1,3,5]triazine-2,4-diamine,
N-(4-*tert*-Butyl-phenyl)-6-(2-fluoro-benzyloxy)-[1,3,5]triazine-2,4-diamine,
N-(4-*tert*-Butyl-phenyl)-6-(2-methoxy-benzyloxy)-[1,3,5]triazine-2,4-diamine,
N-(4-*tert*-Butyl-phenyl)-6-chloro-N'-(2-chloro-benzyl)-[1,3,5]triazine-2,4-diamine,
N-(4-*tert*-Butyl-phenyl)-6-chloro-N'-(2-fluoro-benzyl)-[1,3,5]triazine-2,4-diamine,
N-(4-*tert*-Butyl-phenyl)-6-chloro-N'-(2-methoxy-benzyl)-[1,3,5]triazine-2,4-diamine,
N-(4-*tert*-Butyl-phenyl)-6-chloro-N'-(2-trifluoromethyl-benzyl)-[1,3,5]triazine-2,4-diamine,
N-(4-*tert*-Butyl-phenyl)-N'-(2-chloro-benzyl)-[1,3,5]triazine-2,4,6-triamine,
N-(4-*tert*-Butyl-phenyl)-N'-(2-chloro-benzyl)-6-ethoxy-[1,3,5]triazine-2,4-diamine,
N-(4-*tert*-Butyl-phenyl)-N'-(2-chloro-benzyl)-6-methoxy-[1,3,5]triazine-2,4-diamine,
N-(4-*tert*-Butyl-phenyl)-N'-(2-chloro-benzyl)-6-methyl-[1,3,5]triazine-2,4-diamine,
N-(4-*tert*-Butyl-phenyl)-N'-(2-chloro-benzyl)-N''-methyl-[1,3,5]triazine-2,4,6-triamine,
N-(4-*tert*-Butyl-phenyl)-N'-(2-chloro-benzyl)-pyrimidine-4,6-diamine,
N-(4-*tert*-Butyl-phenyl)-N'-(2-fluoro-benzyl)-[1,3,5]triazine-2,4,6-triamine,
N-(4-*tert*-Butyl-phenyl)-N'-(2-fluoro-benzyl)-pyrimidine-4,6-diamine,
N-(4-*tert*-Butyl-phenyl)-N'-(2-methoxy-benzyl)-[1,3,5]triazine-2,4-diamine,
N-(4-*tert*-Butyl-phenyl)-N'-(2-methoxy-benzyl)-[1,3,5]triazine-2,4,6-triamine,
N-(4-*tert*-Butyl-phenyl)-N'-(2-methoxy-benzyl)-pyrimidine-4,6-diamine,
N-(4-*tert*-Butyl-phenyl)-N'-(2-trifluoromethyl-benzyl)-[1,3,5]triazine-2,4,6-triamine,
N-(4-*tert*-Butyl-phenyl)-N'-(2-trifluoromethyl-benzyl)-pyrimidine-4,6-diamine,
N-(4-*tert*-Butyl-phenyl)-N'-(3-fluoro-benzyl)-pyrimidine-4,6-diamine,
N-(4-*tert*-Butyl-phenyl)-N'-(3-methoxy-benzyl)-pyrimidine-4,6-diamine,
N-(4-*tert*-Butyl-phenyl)-N'-(4-chloro-benzyl)-pyrimidine-4,6-diamine,
N-(4-*tert*-Butyl-phenyl)-N'-(4-methoxy-benzyl)-pyrimidine-4,6-diamine,

N-(4-*tert*-Butyl-phenyl)-N',N''-bis-(2-chloro-benzyl)-[1,3,5]triazine-2,4,6-triamine,

N-(4-*tert*-Butyl-phenyl)-N',N''-bis-(2-methoxy-benzyl)-[1,3,5]triazine-2,4,6-triamine,

N-(4-*tert*-Butyl-phenyl)-N'-pyridin-2-ylmethyl-pyrimidine-4,6-diamine,

N-(4-*tert*-Butyl-phenyl)-N'-pyridin-3-ylmethyl-pyrimidine-4,6-diamine,

N-(4-*tert*-Butyl-phenyl)-N'-pyridin-4-ylmethyl-pyrimidine-4,6-diamine,

N,N-Diethyl-6-(2-trifluoromethyl-benzyloxy)-N'-(4-trifluoromethyl-phenyl)-[1,3,5]triazine-2,4-diamine,

N4-(4-*tert*-Butyl-phenyl)-6-(2-trifluoromethyl-benzyloxy)-pyrimidine-2,4-diamine,

N-Benzyl-N'-(4-*tert*-butyl-phenyl)-pyrimidine-4,6-diamine,

N-Butyl-6-(2-trifluoromethyl-benzyloxy)-N'-(4-trifluoromethyl-phenyl)-[1,3,5]triazine-2,4-diamine,

N-Cyclobutyl-6-(2-trifluoromethyl-benzyloxy)-N'-(4-trifluoromethyl-phenyl)-[1,3,5]triazine-2,4-diamine,

N-Cyclohexyl-6-(2-trifluoromethyl-benzyloxy)-N'-(4-trifluoromethyl-phenyl)-[1,3,5]triazine-2,4-diamine,

N-Cyclopentyl-6-(2-trifluoromethyl-benzyloxy)-N'-(4-trifluoromethyl-phenyl)-[1,3,5]triazine-2,4-diamine,

N-Isobutyl-6-(2-trifluoromethyl-benzyloxy)-N'-(4-trifluoromethyl-phenyl)-[1,3,5]triazine-2,4-diamine,

N-Isopropyl-6-(2-trifluoromethyl-benzyloxy)-N'-(4-trifluoromethyl-phenyl)-[1,3,5]triazine-2,4-diamine, and

N-*tert*-Butyl-6-(2-trifluoromethyl-benzyloxy)-N'-(4-trifluoromethyl-phenyl)-[1,3,5]triazine-2,4-diamine, or a pharmaceutically acceptable ~~form~~salt thereof.

114-180. (Cancelled).

181. (New) A pharmaceutical composition, comprising at least one compound or pharmaceutically acceptable salt thereof according to claim 28 in combination with a physiologically acceptable carrier or excipient.

182. (New) A pharmaceutical composition according to claim 181 wherein the composition is formulated as an injectible fluid, an aerosol, a cream, a gel, a pill, a capsule, a syrup or a transdermal patch.

183. (New) A pharmaceutical composition, comprising at least one compound or pharmaceutically acceptable salt thereof according to claim 43 in combination with a physiologically acceptable carrier or excipient.

184. (New) A pharmaceutical composition according to claim 183 wherein the composition is formulated as an injectible fluid, an aerosol, a cream, a gel, a pill, a capsule, a syrup or a transdermal patch.